Gynecology and Obstetrics Research · Vol. 3, No. 1 · 2016 · pp. 1–6 · e-ISSN 2377-1542

Developmental Exposure to Endocrine Disrupting Chemicals Alters the Epigenome: Identification of Reprogrammed Targets

Lauren Prusinski, Ayman Al-Hendy, Qiwei Yang

Division of Translation Research, Department of Obstetrics and Gynecology, Augusta University, Medical College of Georgia, Augusta, GA, USAUnited States

DOI: https://doi.org/10.17140/goroj-3-127 · Published 2016-05-03 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2016 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Endocrine disruptions induced by environmental toxicants have placed an immense burden on society to properly diagnose, treat and attempt to alleviate symptoms and disease. Environmental exposures during critical periods of development can permanently reprogram normal physiological responses, thereby increasing susceptibility to disease later in life – a process known as developmental reprogramming. During development, organogenesis and tissue differentiation occur through a continuous series of tightly regulated and precisely-timed molecular, bio chemical and cellular events. Humans may encounter Endocrine Disrupting Chemicals (EDCs) daily and during all stages of life, from conception and fetal development through adulthood and senescence. Though puberty and perimenopausal periods may be affected by endocrine disruption due to hormonal effects, prenatal and early postnatal windows are most critical for proper development due to rapid changes in system growth. Developmental reprogramming is shown to be caused by alterations in the epigenome. Development is the time when epigenetic programs are ‘installed’ on the genome by ‘writers’, such as histone methyltransferases (HMTs) and DNA methyltransferases (DNMTs), which add methyl groups to lysine and arginine residues on histone tails and to CpG sites in DNA, respectively. A number of environmental compounds, referred to as Estrogenic Endocrine Disruptors (EEDs), are able to bind to Estrogen Receptors (ERs) and interfere with the normal cellular development in target tissues including the prostate and uterus. These EEDs, including diethylstilbestrol (DES), bisphenol A (BPA), and genistein (a phytoestrogen derived from soybeans), have been implicated in the malformation of reproductive organs and later development of disease. Due to the lack of fully understanding the underlying mechanisms of how environmental toxicants and their level of exposure affect the human genome, it can be challenging to create clear clinical guidance to address the potential health effects of lower-level exposures commonly experienced within the general population. In addition, human studies concerning environmental exposures are limited in feasibility by ethical concerns for human safety. Therefore, studies in animal models provide great opportunities to reveal links between early-life exposure to EDCs and related diseases. It has been shown that developmental exposure to EDCs, such as diethylstilbestrol (DES) and genistein, during reproductive tract development increases the incidence, multiplicity and overall size of uterine fibroids in the Eker rat model, concomitantly reprogramming estrogen-responsive gene expression. Importantly, EDC exposure represses enhancer of zeste 2 (EZH2) and reduces levels of the histone 3 lysine 27 trimethylation (H3K27me3) repressive mark through Estrogen receptor/Phosphatidylinositide 3-kinases/Protein kinase B non-genomic signaling in the developing uterus. More recent research identified a developmental reprogramming target, Scbg2a1 gene, whose epigenetic status can be altered by early exposure to BPA in the rat prostate. Molecular analyses revealed markedly increased expression (greater than 100 fold) of Scgb2a1, a secretaglobin gene in response to developmental exposure to BPA. This increase in Scgb2a1 expression is concomitantly associated with increased enrichment of acetylated H3K9 (H3K9Ac representing active chromatin status) and hypomethylation of DNA for a CpG island upstream of the transcription start site of Scgb2a1. These data suggest that expression of Scgb2a1 in the adult prostate could be epigenetically reprogrammed by BPA exposure during prostate development. Further studies are needed to create more targeted preventative interventions as well as specific, effective therapeutics to decrease the incidence of diseases.

Keywords: Developmental environmental exposure; Endocrine disrupting chemicals; Epigenetics; Prostate; Fibroids

Acknowledgement

This work was supported in part by an Augusta University Startup package, the National Institutes of Health grant HD04622811 (to AA), and the Augusta University Intramural Grants Program (QY). We would like to thank Walidah Walker, MPH for editing this manuscript.

Conflicts Of Interest

None of the authors have a financial relationship with a commer- 16 cial entity that has an interest in the subject of this manuscript.

References

  1. HeindelJJ. Role of exposure to environmental chemicals in the developmental basis of reproductive disease and dysfunction. Semin Reprod Med. 2006; 24(3): 168-177. doi: 10.1055/s- 2006-94442310.1055/s-2006-944423 https://doi.org/10.1055/s-2006-944423
  2. WalkerCLHoSM. Developmental reprogramming of cancer susceptibility. Nat Rev Cancer. 2012; 12(7): 479-486. doi: 10.1038/nrc322010.1038/nrc3220 https://doi.org/10.1038/nrc3220
  3. TrasandeLZoellerRTHassU. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union. J Clin Endocrinol Metab. 2015; 100(4):1245-1255. doi: 10.1210/jc.2014-432410.1210/jc.2014-4324 https://doi.org/10.1210/jc.2014-4324
  4. GoreACHeindelJJZoellerRT. Endocrine disruption for endocrinologists (and others). Endocrinology. 2006; 147(6 Suppl): S1-S3. doi: 10.1210/en.2005-136710.1210/en.2005-1367 https://doi.org/10.1210/en.2005-1367
  5. CrewsDMcLachlanJA. Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology. 2006; 147(6 Suppl): S4-S10 doi: 10.1210/en.2005-112210.1210/en.2005-1122 https://doi.org/10.1210/en.2005-1122
  6. ChevalierNFenichelP. Endocrine disruptors: new players in the pathophysiology of type 2 diabetes? Diabetes Metab. 2015; 41(2): 107-115. doi: 10.1016/j.diabet.2014.09.00510.1016/j.diabet.2014.09.005 https://doi.org/10.1016/j.diabet.2014.09.005
  7. RoseboomTJ. Undernutrition during fetal life and the risk of cardiovascular disease in adulthood. Future cardiology. 2012; 8(1): 5-7. doi: 10.2217/fca.11.8610.2217/fca.11.86 https://doi.org/10.2217/fca.11.86
  8. CookJDDavisBJCaiSLBarrettJCContiCJWalkerCL. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc Natl Acad Sci U S A. 2005; 102(24): 8644-8649. doi: 10.1073/pnas.050321810210.1073/pnas.0503218102 https://doi.org/10.1073/pnas.0503218102
  9. CookJDADavisBJGoeweyJABerryTDWalkerCL. Identification of a sensitive period for developmental programming that increases risk for uterine leiomyoma in Eker rats. Reprod Sci. 2007; 14(2): 121-136. doi: 10.1177/193371910629840110.1177/1933719106298401 https://doi.org/10.1177/1933719106298401
  10. BernalAJJirtleRL. Epigenomic disruption: the effects of early developmental exposures. Birth Defects Res A Clin Mol Teratol. 2010; 88(10): 938-944. doi: 10.1002/bdra.2068510.1002/bdra.20685 https://doi.org/10.1002/bdra.20685
  11. AntoniouAPharoahPDNarodS. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American journal of human genetics. 2003; 72(5):1117-1130. doi: 10.1086/37503310.1086/375033 https://doi.org/10.1086/375033
  12. HellerK. Genetic counseling: DNA testing for the patient. Proceedings. 2005; 18(2):134-137. Web site. http://www.ncbi. nlm.nih.gov/pmc/articles/PMC1200714/. Accessed February 17, 2016
  13. LyLChanDTraslerJM. Developmental windows of susceptibility for epigenetic inheritance through the male germline. Semin Cell Dev Biol. 2015; 43: 96-105 doi: 10.1016/j. semcdb.2015.07.00610.1016/j.semcdb.2015.07.006 https://doi.org/10.1016/j.semcdb.2015.07.006
  14. SandoviciIHammerleCMOzanneSEConstanciaM. Developmental and environmental epigenetic programming of the endocrine pancreas: consequences for type 2 diabetes. Cell Mol Life Sci. 2013; 70(9): 1575-1595. doi: 10.1007/s00018-013- 1297-110.1007/s00018-013-1297-1 https://doi.org/10.1007/s00018-013-1297-1
  15. CantoneIFisherAG. Epigenetic programming and reprogramming during development. Nature structural & molecular
  16. LiHRichardsonWD. Genetics meets epigenetics: HDACs and Wnt signaling in myelin development and regeneration. Nat Neurosci. 2009; 12(7): 815-817. doi: 10.1038/nn0709-81510.1038/nn0709-815 https://doi.org/10.1038/nn0709-815
  17. StuppiaLFranzagoMBalleriniPGattaVAntonucciI. Epigenetics and male reproduction: the consequences of paternal lifestyle on fertility, embryo development, and children lifetime health. Clinical epigenetics. 2015; 7:120 doi: 10.1186/ s13148-015-0155-4
  18. RasmussenTP. The epigenetics of early development: inferences from stem cells. Mol Reprod Dev. 2014; 81(2): 194-201. doi: 10.1002/mrd.2226910.1002/mrd.22269 https://doi.org/10.1002/mrd.22269
  19. Van de Vijver G, Van Speybroeck L, De Waele D. Epigenetics: a challenge for genetics, evolution, and development? Ann N Y Acad Sci. 2002; 981:1-6. doi: 10.1111/j.1749- 6632.2002.tb04909.x https://doi.org/10.1111/j.1749-6632.2002.tb04909.x
  20. TrevinoLSWangQWalkerCL. Phosphorylation of epigenetic "readers, writers and erasers": Implications for developmental reprogramming and the epigenetic basis for health and disease. Prog Biophys Mol Biol. 2015; 118(1-2): 8-13 doi: 10.1016/j.pbiomolbio.2015.02.01310.1016/j.pbiomolbio.2015.02.013 https://doi.org/10.1016/j.pbiomolbio.2015.02.013
  21. DawsonMAKouzaridesTHuntlyBJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012; 367(7): 647-657. doi: 10.1056/NEJMra111263510.1056/nejmra1112635 https://doi.org/10.1056/nejmra1112635
  22. BerdascoMEstellerM. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010; 19(5): 698-711. doi: 10.1016/j.devcel.2010.10.00510.1016/j.devcel.2010.10.005 https://doi.org/10.1016/j.devcel.2010.10.005
  23. RuthenburgAJLiHPatelDJAllisCD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol. 2007; 8(12): 983-994. doi: 10.1038/ nrm2298
  24. TanLShiYG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development. 2012; 139(11): 1895-1902. doi: 10.1242/dev.07077110.1242/dev.070771 https://doi.org/10.1242/dev.070771
  25. YangQMasADiamondMPAl-HendyA. The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development. Reprod Sci. 2015; 23(2): 163-175. doi: 10.1177/193371911558444910.1177/1933719115584449 https://doi.org/10.1177/1933719115584449
  26. BredfeldtTGGreathouseKLSafeSHHungMCBedfordMTWalkerCL. Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/ AKT. Mol Endocrinol. 2010; 24(5): 993-1006. doi: 10.1210/ me.2009-0438
  27. GreathouseKLBredfeldtTEverittJI. Environmental estrogens differentially engage the histone methyltransferase 2012; 10(4): 546-557. doi: 10.1158/1541-778610.1158/1541-7786 https://doi.org/10.1158/1541-7786
  28. HuangYRaoA. Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet. 2014; 30(10): 464-474. doi: 10.1016/j.tig.2014.07.00510.1016/j.tig.2014.07.005 https://doi.org/10.1016/j.tig.2014.07.005
  29. PrinsGSHuWYShiGB. Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium. Endocrinology. 2014; 155(3): 805-817. doi: 10.1210/en.2013-195510.1210/en.2013-1955 https://doi.org/10.1210/en.2013-1955
  30. WongRLWangQTrevinoLS. Identification of secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate. Epigenetics. 2015; 10(2):127-134. doi: 10.1080/15592294.2015.100976810.1080/15592294.2015.1009768 https://doi.org/10.1080/15592294.2015.1009768